I-13 Henning Schmidt The “SBPOP Package”: Efficient Support for Model Based Drug Development – From Mechanistic Models to Complex Trial Simulation Wednesday 10:05-11:40 |
I-17 Catherine Sherwin Dense Data - Methods to Handle Massive Data Sets without Compromise Wednesday 10:05-11:40 |
I-20 Hankil Son A conditional repeated time-to-event analysis of onset and retention times of sildenafil erectile response Wednesday 10:05-11:40 |
I-44 Anne van Rongen Population pharmacokinetic model characterising the influence of circadian rhythm on the pharmacokinetics of oral and intravenous midazolam in healthy volunteers Wednesday 10:05-11:40 |
I-60 Klintean Wunnapuk Population analysis of paraquat toxicokinetics in poisoning patients Wednesday 10:05-11:40 |
II-10 Martin Fink Animal Health Modeling & Simulation Society (AHM&S): A new society promoting model-based approaches for a better integration and understanding of quantitative pharmacology in Veterinary Sciences Wednesday 14:50-16:20 |
II-11 Sylvain Fouliard Semi-mechanistic population PKPD modelling of a surrogate biomarker Wednesday 14:50-16:20 |
II-13 Chris Franklin : Introducing DDMoRe’s framework within an existing enterprise modelling and simulation environment. Wednesday 14:50-16:20 |
II-18 Peter Gennemark Incorporating model structure uncertainty in model-based drug discovery Wednesday 14:50-16:20 |
II-28 José David Gómez-Mantilla Tailor-made dissolution profile comparisons using in vitro-in vivo correlation models. Wednesday 14:50-16:20 |
II-32 Bruce Green Clinical Application of a K-PD Warfarin Model for Bayesian Dose Individualisation in Primary Care Wednesday 14:50-16:20 |
II-45 Lorenzo Ridolfi Predictive Modelling Environment - Infrastructure and functionality for pharmacometric activities in R&D Wednesday 14:50-16:20 |
II-53 Niclas Jonsson Population PKPD analysis of weekly pain scores after intravenously administered tanezumab, based on pooled Phase 3 data in patients with osteoarthritis of the knee or hip Wednesday 14:50-16:20 |
II-64 Julia Korell Gaining insight into red blood cell destruction mechanisms using a previously developed semi-mechanistic model Wednesday 14:50-16:20 |
III-14 Yan Li Modeling and Simulation to Probe the Likely Difference in Pharmacokinetic Disposition of R- and S-Enantiomers Justifying the Development of Racemate Pomalidomide Thursday 10:05-11:35 |
III-15 Lia Liefaard Predicting levels of pharmacological response in long-term patient trials based on short-term dosing PK and biomarker data from healthy subjects Thursday 10:05-11:35 |
III-16 Karl-Heinz Liesenfeld Pharmacometric Characterization of the Elimination of Dabigatran by Haemodialysis Thursday 10:05-11:35 |
III-24 Merran Macpherson Using modelling and simulation to evaluate potential drug repositioning to a new therapy area Thursday 10:05-11:35 |
III-28 Hafedh Marouani Dosage regimen individualization of the once-daily amikacin treatment by using kinetics nomograms. Thursday 10:05-11:35 |
III-30 María Isabel Mas Fuster Stochastic Simulations Assist to Select the Intravenous Digoxin Dosing Protocol in Elderly Patients in Acute Atrial Fibrillation Thursday 10:05-11:35 |
III-45 Tram Nguyen Influence of a priori information, designs and undetectable data on individual parameters estimation and prediction of hepatitis C treatment outcome Thursday 10:05-11:35 |
III-51 Fredrik Öhrn Longitudinal Modelling of FEV1 Effect of Bronchodilators Thursday 10:05-11:35 |
IV-12 Ioanna Athanasiadou Simulation of the effect of hyperhydration on urine levels of recombinant human erythropoietin from a doping control point of view Thursday 14:55-16:20 |
IV-18 Marcus Björnsson Effect on bias in EC50 when using interval censoring or exact dropout times in the presence of informative dropout Thursday 14:55-16:20 |
IV-33 Theresa Cain Prediction of Rosiglitazone compliance from last sampling information using Population based PBPK modelling and Bayes theorem: Comparison of prior distributions for compliance. Thursday 14:55-16:20 |
IV-38 Phylinda Chan Industry Experience in Establishing a Population Pharmacokinetic Analysis Guidance Thursday 14:55-16:20 |
IV-43 Nianhang Chen Comparison of Two Parallel Computing Methods (FPI versus MPI) in NONMEM 7.2 on complex popPK and popPK/PD Models Thursday 14:55-16:20 |
IV-44 Marylore Chenel Population Pharmacokinetic Modelling to Detect Potential Drug Interaction Using Sparse Sampling Data Thursday 14:55-16:20 |